Commentary: anthracyclines in early-stage breast cancer: is it the end of an era?
Pritchard
Kathleen I
KI
Sunnybrook Health Sciences Centre, 2075 Bayview Ave., Toronto, Ontario M4N 3M5, Canada. Kathy.Pritchard@sunnybrook.ca
D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D018579:Patient Selection; D016896:Treatment Outcome
D018943:Anthracyclines; D000970:Antineoplastic Agents